Mothers & Babies Research Centre and School of Biomedical Sciences, University of Newcastle, Newcastle, NSW, Australia.
J Neuroendocrinol. 2010 Mar;22(3):166-74. doi: 10.1111/j.1365-2826.2009.01949.x. Epub 2009 Dec 23.
There are ongoing concerns that antenatal corticosteroids, which are administered to women at high risk of delivering preterm to reduce the incidence of respiratory distress syndrome, have adverse effects on foetal brain development and subsequent effects on behaviour and learning, when administered as repeated courses. The present study aimed to examine whether repeated betamethasone treatment alters the expression of the key-rate limiting enzyme, 5alpha-reductase, in the synthetic pathway of the potent neuroactive steroid allopregnanolone in the brain and placenta and whether this effect is potentiated in growth restricted foetuses. To investigate this, pregnant guinea pigs carrying either control (sham surgery) or growth-restricted foetuses were treated with vehicle or betamethasone (1 mg/kg/day) for 4 days prior to sacrifice (65d). Placental insufficiency was induced by the ablation of uterine artery branches supplying each placenta at mid gestation, resulting in foetal growth restriction characterised by 'brain sparing'. Real-time reverse transcriptase polymerase chain reaction was used to determine relative 5alpha-reductase type 1 and 2 mRNA expression in the placenta and brain. Immunohistochemistry was used to examine the glial fibrillary acidic protein (GFAP) expression in the subcortical white matter, CA1 and dentate regions of the hippocampus. 5alpha-reductase type 2 mRNA expression in the brain was markedly reduced by betamethasone treatment in male foetuses compared to vehicle-treated controls but not in female foetuses. In addition, 5alpha-reductase type 1 expression in the brain was increased by growth restriction and/or betamethasone treatment in female foetuses but expression in males foetuses did not increase. 5alpha-reductase type 2 expression in the placenta was markedly reduced by betamethasone treatment compared to vehicle-treated control. Intrauterine growth restriction and betamethasone treatment reduced GFAP expression in the CA1 region of the hippocampus in the brains of male but not female foetuses. These data indicate that betamethasone treatment suppresses placental expression and has sexually dimorphic effects on expression of neuroactive steroid synthetic enzymes in the brain. These actions may lead to adverse effects on the developing brain, particularly in male foetuses, such as the observed effects on GFAP expression.
人们一直担心,产前皮质类固醇(antenatal corticosteroids)用于有早产风险的孕妇,以降低呼吸窘迫综合征的发生率,但如果反复使用,会对胎儿的大脑发育产生不良影响,并对行为和学习产生后续影响。本研究旨在探讨重复使用倍他米松是否会改变关键限速酶 5α-还原酶在脑和胎盘内强效神经活性甾体孕烷醇酮合成途径中的表达,以及这种影响是否在生长受限的胎儿中增强。为了研究这一点,携带对照(假手术)或生长受限胎儿的怀孕豚鼠在牺牲前(65 天)用载体或倍他米松(1mg/kg/天)处理 4 天。在妊娠中期通过消融每个胎盘供应的子宫动脉分支来诱导胎盘功能不全,导致胎儿生长受限,表现为“脑保留”。实时逆转录聚合酶链反应用于确定胎盘和脑中 5α-还原酶 1 型和 2 型 mRNA 的相对表达。免疫组织化学用于检查皮质下白质、海马 CA1 和齿状回的胶质纤维酸性蛋白(GFAP)表达。与载体处理的对照组相比,倍他米松处理明显降低了雄性胎儿脑中的 5α-还原酶 2 型 mRNA 表达,但对雌性胎儿没有影响。此外,生长受限和/或倍他米松处理增加了雌性胎儿脑中的 5α-还原酶 1 型表达,但雄性胎儿的表达没有增加。与载体处理的对照组相比,倍他米松处理明显降低了胎盘 5α-还原酶 2 型的表达。宫内生长受限和倍他米松处理降低了雄性胎儿而非雌性胎儿海马 CA1 区的 GFAP 表达。这些数据表明,倍他米松处理抑制了胎盘表达,并对脑内神经活性甾体合成酶的表达产生性别二态影响。这些作用可能会对发育中的大脑产生不良影响,特别是在雄性胎儿中,如观察到的对 GFAP 表达的影响。